Aesica Announces FDA Approvals for Germany Facility
Aesica announced that it received continuing approvals from FDA for its bulk manufacturing and packaging operations in Germany.
Aesica, which is a contract development and manufacturing organization, announced on Feb. 2, 2015 that it would continue to grow its manufacturing and packaging services of pharmaceutical products bound for the United States. This announcement comes after the company received FDA pre-approvals for its Germany facilities in Zwickau and Monheim.
The Zwickau site offers bulk manufacture of pharmaceutical tablets, capsules, and controlled release products, with more than 90 products from more than 40 APIs. The Monheim facility houses logistics and distribution centers, with packaging for 1100 SKUs with multiple indications for all geographic markets. In addition to FDA approvals, the sites have also attained successful inspections from ANVISA (for the Brazilian market) and from the German Health Agency.
Source: Aesica
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
